Introducing Koala Prospector! Bringing Waterfall Enrichment to Reps

Learn More!
Ciloa

Ciloa

Ciloa is dedicated to the development of new high potential therapies. It was built on more than 15 years of research on bio-drug development technology using exosomes. Ciloa's technology allows to address oncology, infectiology, cardiology, genetic and neurological diseases, and more. Our technology is the only one allowing to produce all types of membrane proteins with their native conformation on exosomes. It allows to load exosomes with cytosolic proteins as well. It thus makes it possible to reach the most difficult families of membrane protein targets, known as "undruggable", some being the most promising for therapies. Ciloa takes advantage of the natural properties of exosomes; they are natural immuno-stimulators, biocompatible, intercellular membrane messengers, and able to cross all the human body barriers including the blood-brain barrier.

Last updated on

About Ciloa

Founded

2011

Estimated Revenue

$10M-$50M

Employees

11-50

Funding / Mkt. Cap

$5M

Category

Industry

Biotechnology

Location

City

Montpellier

State

Occitania

Country

France

Tech Stack (0)

search